US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NewcelX Ltd.

3.26

-0.1073-3.18%

Post-market: 3.260.00000.00%19:30 EDT

Volume:1K

Turnover:4.58K

Market Cap:17.44M

PE:-1.51

High:3.31

Open:3.31

Low:3.22

Close:3.37

52wk High:28.03

52wk Low:1.83

Shares:5.35M

Float Shares:2.74M

Volume Ratio:0.08

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1600

EPS(LYR):-2.1592

ROE:--

ROA:-25.94%

PB:2.41

PE(LYR):-1.51

Loading ...

Overview Company News Filings

Newcelx Ag - Type B Pre-Ind Meeting With FDA Scheduled for Last Week of June

THOMSON REUTERS

Newcelx Ltd. Submits Pre-Ind Package to the FDA for Ncel-101 for the Treatment of Type 1 Diabetes

THOMSON REUTERS

NewcelX FY EPS $(2.16) Up From $(2.43) YoY

Benzinga Earnings

Newcelx Reports Financial Results for 2025 and Provides Shareholders With Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration With Eledon Pharmaceuticals in 2026

THOMSON REUTERS

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

Benzinga Earnings

NewcelX FY25 net loss widens to USD 8.3 million; operating loss rises to USD 2.56 million

BRIEF-Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program

NewcelX publishes updated corporate presentation

Newcelx Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration With Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

NewcelX prices $1.35 million private placement at 30% premium to market

Newcelx Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

THOMSON REUTERS

NewcelX AG files Form 3 for Chairman and CEO Ronen Twito

NewcelX AG director Iohan Eran Israel files initial beneficial ownership statement

NewcelX AG director Alexander Zwyer files initial beneficial ownership statement

BRIEF-NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

Newcelx Ag - Collaboration to Integrate Ncel-101 With Eledon's Tegoprubart (at-1501)

THOMSON REUTERS

Newcelx Announces Strategic Collaboration With Eledon Pharmaceuticals to Advance Ncel-101 Program for Type 1 Diabetes

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NCEL/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":3.2627,"timestamp":1787342400000,"preClose":3.37,"halted":0,"volume":1395,"hourTrading":{"tag":"盘后","latestPrice":3.2627,"preClose":3.2627,"latestTime":"19:30 EDT","volume":8,"amount":26.88,"timestamp":1787355006084,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03183976261127595,"floatShares":2738900,"shares":5345200,"eps":-2.159999,"marketStatus":"Market Closed","change":-0.1073,"latestTime":"08-21 16:00:00 EDT","open":3.31,"high":3.31,"low":3.2153,"amount":4579.99983,"amplitude":0.028101,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.159999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":3.37,"preHourTrading":{"tag":"盘前","latestPrice":3.37,"preClose":3.37,"latestTime":"08:51 EDT","volume":35,"amount":117.95,"timestamp":1787316695357,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.2627,"preClose":3.2627,"latestTime":"19:30 EDT","volume":8,"amount":26.88,"timestamp":1787355006084,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.08353693500067978},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","floatShares":2738900,"roa":"-25.94%","roe":"--","lyrEps":-2.159218,"volumeRatio":0.08353693500067978,"shares":5345200,"dividePrice":0,"high":3.31,"amplitude":0.028101,"preClose":3.37,"low":3.2153,"week52Low":1.8299,"pbRate":"2.41","week52High":28.032,"institutionHeld":0,"latestPrice":3.2627,"eps":-2.159999,"divideRate":0,"volume":1395,"delay":0,"ttmEps":-2.159999,"open":3.31,"prevYearClose":1.9,"prevWeekClose":3.345,"prevMonthClose":3.49,"prevQuarterClose":3.66,"fiveDayClose":3.345,"twentyDayClose":3.755,"sixtyDayClose":3.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-04-30","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-10-31","symbol":"NCEL","defaultRemindTime":1761917400000,"type":"split","dateTimestamp":1761883200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-16","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1747368000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-09-27","symbol":"NCEL","defaultRemindTime":1727443800000,"type":"split","dateTimestamp":1727409600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCEL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCEL","date":"2026-08-21","current":-1.51051,"percent":0.18593,"low":-2.743828,"twenty":-2.167171,"median":-0.833563,"eighty":-0.589629,"high":-0.434312,"avg":-1.267621,"sd":0.777563,"marketCap":18143645},"quantilePoints":[{"date":"2025-10-31","current":-2.085416,"twenty":-2.085416,"median":-2.085416,"eighty":-2.085416,"marketCap":39937082.48},{"date":"2025-11-07","current":-0.993097,"twenty":-1.495376,"median":-1.229626,"eighty":-1.098389,"marketCap":18917268},{"date":"2025-11-14","current":-0.808829,"twenty":-1.253274,"median":-0.970727,"eighty":-0.876223,"marketCap":15635236},{"date":"2025-11-21","current":-0.750891,"twenty":-1.145695,"median":-0.878334,"eighty":-0.814355,"marketCap":14358890},{"date":"2025-11-28","current":-0.957951,"twenty":-1.045743,"median":-0.867781,"eighty":-0.806793,"marketCap":18279095},{"date":"2025-12-05","current":-0.856292,"twenty":-0.972009,"median":-0.871696,"eighty":-0.812974,"marketCap":16455744},{"date":"2025-12-12","current":-0.781666,"twenty":-0.995845,"median":-0.875612,"eighty":-0.812974,"marketCap":15179398},{"date":"2025-12-19","current":-0.635834,"twenty":-0.972009,"median":-0.85736,"eighty":-0.781019,"marketCap":12353204},{"date":"2025-12-26","current":-0.613233,"twenty":-0.957493,"median":-0.83848,"eighty":-0.693066,"marketCap":11988534},{"date":"2026-01-02","current":-0.442896,"twenty":-0.955117,"median":-0.833152,"eighty":-0.615876,"marketCap":8660918},{"date":"2026-01-09","current":-0.513637,"twenty":-0.941907,"median":-0.808829,"eighty":-0.589968,"marketCap":10074015},{"date":"2026-01-16","current":-0.561129,"twenty":-0.915578,"median":-0.78535,"eighty":-0.566624,"marketCap":11122442},{"date":"2026-01-23","current":-0.610165,"twenty":-0.913462,"median":-0.76547,"eighty":-0.561129,"marketCap":12125285},{"date":"2026-01-30","current":-0.576613,"twenty":-0.882218,"median":-0.6841,"eighty":-0.565731,"marketCap":11623863},{"date":"2026-02-06","current":-0.601541,"twenty":-0.878334,"median":-0.628521,"eighty":-0.570197,"marketCap":12034117},{"date":"2026-02-13","current":-0.627168,"twenty":-0.875612,"median":-0.627168,"eighty":-0.572325,"marketCap":12717874},{"date":"2026-02-20","current":-0.632256,"twenty":-0.869347,"median":-0.627168,"eighty":-0.573006,"marketCap":12581123},{"date":"2026-02-27","current":-0.656951,"twenty":-0.860299,"median":-0.626808,"eighty":-0.575926,"marketCap":13082544},{"date":"2026-03-06","current":-0.638142,"twenty":-0.856719,"median":-0.630594,"eighty":-0.581513,"marketCap":12854625},{"date":"2026-03-13","current":-0.639458,"twenty":-0.843011,"median":-0.628376,"eighty":-0.587749,"marketCap":12717874},{"date":"2026-03-20","current":-0.559522,"twenty":-0.837754,"median":-0.626853,"eighty":-0.587749,"marketCap":11168026},{"date":"2026-03-27","current":-0.565498,"twenty":-0.835865,"median":-0.623182,"eighty":-0.571899,"marketCap":11259193},{"date":"2026-04-02","current":-0.537802,"twenty":-0.83268,"median":-0.620613,"eighty":-0.56375,"marketCap":10712188},{"date":"2026-04-10","current":-0.468376,"twenty":-0.821759,"median":-0.618412,"eighty":-0.555851,"marketCap":9527010},{"date":"2026-04-17","current":-0.546102,"twenty":-0.811592,"median":-0.616697,"eighty":-0.55169,"marketCap":11350361},{"date":"2026-04-24","current":-1.072253,"twenty":-0.811592,"median":-0.617492,"eighty":-0.552903,"marketCap":22381635},{"date":"2026-05-01","current":-0.95322,"twenty":-0.83268,"median":-0.620255,"eighty":-0.55452,"marketCap":20102446},{"date":"2026-05-08","current":-1.779415,"twenty":-0.838489,"median":-0.62112,"eighty":-0.555851,"marketCap":14769144},{"date":"2026-05-15","current":-2.224901,"twenty":-0.870913,"median":-0.625846,"eighty":-0.556353,"marketCap":18466677},{"date":"2026-05-22","current":-2.062736,"twenty":-0.91452,"median":-0.627168,"eighty":-0.558257,"marketCap":17120709},{"date":"2026-05-29","current":-2.296253,"twenty":-0.955372,"median":-0.628812,"eighty":-0.55988,"marketCap":19058903},{"date":"2026-06-05","current":-2.043276,"twenty":-1.009476,"median":-0.634045,"eighty":-0.560702,"marketCap":16959193},{"date":"2026-06-12","current":-2.118586,"twenty":-1.18766,"median":-0.639458,"eighty":-0.562877,"marketCap":17584261},{"date":"2026-06-18","current":-2.043276,"twenty":-1.814564,"median":-0.642142,"eighty":-0.565545,"marketCap":16959193},{"date":"2026-06-26","current":-2.30274,"twenty":-1.957423,"median":-0.652667,"eighty":-0.566624,"marketCap":19112742},{"date":"2026-07-02","current":-2.497338,"twenty":-2.043276,"median":-0.658096,"eighty":-0.570197,"marketCap":20727903},{"date":"2026-07-10","current":-2.678962,"twenty":-2.05625,"median":-0.697542,"eighty":-0.572325,"marketCap":22235387},{"date":"2026-07-17","current":-2.536257,"twenty":-2.075709,"median":-0.73457,"eighty":-0.573176,"marketCap":21050935},{"date":"2026-07-24","current":-2.464905,"twenty":-2.085416,"median":-0.750891,"eighty":-0.576613,"marketCap":20458709},{"date":"2026-07-31","current":-2.180403,"twenty":-2.102953,"median":-0.781666,"eighty":-0.580006,"marketCap":18097343},{"date":"2026-08-07","current":-2.166522,"twenty":-2.154845,"median":-0.801508,"eighty":-0.582361,"marketCap":17982129},{"date":"2026-08-14","current":-2.335173,"twenty":-2.160035,"median":-0.815737,"eighty":-0.587749,"marketCap":19381935},{"date":"2026-08-21","current":-2.185981,"twenty":-2.167171,"median":-0.833563,"eighty":-0.589629,"marketCap":18143645}],"updateTime":1787472107903},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCEL\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638577507","title":"Newcelx Ag - Type B Pre-Ind Meeting With FDA Scheduled for Last Week of June","url":"https://stock-news.laohu8.com/highlight/detail?id=2638577507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638577507?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:55","pubTimestamp":1779882900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA6F7JRY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507572","title":"Newcelx Ltd. Submits Pre-Ind Package to the FDA for Ncel-101 for the Treatment of Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507572?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:55","pubTimestamp":1779882900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA6F7JRY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631630398","title":"NewcelX FY EPS $(2.16) Up From $(2.43) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2631630398","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631630398?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:56","pubTimestamp":1777553810,"startTime":"0","endTime":"0","summary":"NewcelX (NASDAQ:NCEL) reported quarterly losses of $(2.16) per share. This is a 11.11 percent increase over losses of $(2.43) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/52169033/newcelx-fy-eps-2-16-up-from-2-43-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQY","NCEL","QLD","QQQA","ONEQ","BK4139","NQmain","NVIW.SI","QQQ","FTEC","QID","JEPQ","NDX","QQQJ","MNQmain","QQQE","SQQQ",".IXIC","QDTE","TQQQ","IYW","TQQY","PSQ","GPIQ","QYLG","QQQM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634773","title":"Newcelx Reports Financial Results for 2025 and Provides Shareholders With Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration With Eledon Pharmaceuticals in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634773","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634773?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:15","pubTimestamp":1777551300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA4KWLWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631348286","title":"EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2631348286","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631348286?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:01","pubTimestamp":1777550469,"startTime":"0","endTime":"0","summary":"NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/04/52166830/exclusive-newcelx-eyes-accelerated-2026-execution-for-diabetes-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631524329","title":"NewcelX FY25 net loss widens to USD 8.3 million; operating loss rises to USD 2.56 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631524329","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631524329?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:03","pubTimestamp":1777496625,"startTime":"0","endTime":"0","summary":"NewcelX posted a total loss of USD 8.3 million for fiscal 2025, widening from 2024.Operating loss expanded to USD 2.56 million, driven by first-time consolidation of NLS operations, higher public-company compliance costs, higher stock-based compensation.Cash and cash equivalents totaled USD 2.2 million at Dec. 31, 2025, with accumulated deficit at USD 84.9 million.Management said existing cash is not sufficient to fund one year of operating requirements, while it explores financing options and points to a USD 25 million committed equity facility plus a USD 1.35 million April 2026 private placement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL7jqr28:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628474053","title":"BRIEF-Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2628474053","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628474053?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:58","pubTimestamp":1776686307,"startTime":"0","endTime":"0","summary":"BRIEF-Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program April 20 (Reuters) - NewcelX AG NCEL.O:NEWCELX UPDATES CORPORATE PRESENTATION TO HIGHLIGHT TYPE 1 DIABETES FL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUA4D31QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628474697","title":"NewcelX publishes updated corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2628474697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628474697?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:37","pubTimestamp":1776685072,"startTime":"0","endTime":"0","summary":"NewcelX published updated corporate presentation highlighting Type 1 Diabetes flagship program NCEL-101.Presentation includes strategic collaboration with Eledon integrating NewcelX stem-cell-derived islet replacement platform with Eledon anti-CD40L monoclonal antibody tegoprubart.Update frames combined approach as strategy to support durable graft survival for Type 1 Diabetes.Management plans to present updated materials at Swiss Biotech Conference.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLbTDVY4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","NCEL","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","ELDN","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628479087","title":"Newcelx Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration With Eledon Pharmaceuticals Ahead of Swiss Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2628479087","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628479087?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:37","pubTimestamp":1776685020,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUA4D31QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624543201","title":"BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2624543201","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624543201?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:53","pubTimestamp":1775065980,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa BiosciencesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL6N40K0PA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DE","TEM","CBRE","FCX","NEM","AGH","TEX","AVY","ZYME","MMSI","WDC","ANIX","SCCO","NKE","PKG","CAG","DIS","HWM","RIVN","SATS","STX","ETN","RH","CYCN","AXSM","RILY","LEXX","PWR","BYND","MO","HMH","LUNR","NCEL","ALKS","PM","XAIR","MU","CVX","INTC","OCGN","NCNO","NNOX","IMUX","BX","JANX","O","MAXN","DXYZ","HON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590904","title":"NewcelX prices $1.35 million private placement at 30% premium to market","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590904","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590904?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:21","pubTimestamp":1775042475,"startTime":"0","endTime":"0","summary":"NewcelX priced a private placement raising USD 1.35 million.Shares sold at USD 2.75 each, a 30% premium to March 31 close.Offering includes warrants for 687,270 shares at USD 3.025 exercise price.Net proceeds earmarked to advance NCEL-101 Type 1 Diabetes program, supported by a previously announced USD 25 million equity line.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1j1Sw2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BN0W2T93.GBP","NCEL","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2V16.EUR","BK4585","IE00BGHQF748.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590941","title":"Newcelx Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590941?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:21","pubTimestamp":1775042460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA3SVZZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620237474","title":"NewcelX AG files Form 3 for Chairman and CEO Ronen Twito","url":"https://stock-news.laohu8.com/highlight/detail?id=2620237474","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620237474?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:07","pubTimestamp":1773832064,"startTime":"0","endTime":"0","summary":"NewcelX filed an Initial Statement of Beneficial Ownership on Form 3 naming Ronen Twito as the reporting person. Twito is listed as a director and as chairman and CEO. The filing reports beneficial ownership of 272,399 ordinary shares held in direct form.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLgqwlR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232055","title":"NewcelX AG director Iohan Eran Israel files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232055","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232055?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831347,"startTime":"0","endTime":"0","summary":"Eran Iohan filed a Form 3 initial statement of beneficial ownership for NewcelX, identifying himself as a director. The filing reported an option to purchase 9,117 ordinary shares at an exercise price of USD 7.62. The option has an expiration date of 11/04/2035.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL42gs4x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620321042","title":"NewcelX AG director Alexander Zwyer files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620321042","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620321042?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:44","pubTimestamp":1773830640,"startTime":"0","endTime":"0","summary":"NewcelX reported an initial statement of beneficial ownership by director Alexander Zwyer. The filing listed an option to purchase 50,143 ordinary shares at a USD 7.62 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4CvpT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618628607","title":"BRIEF-NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628607","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628607?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:20","pubTimestamp":1773055215,"startTime":"0","endTime":"0","summary":"BRIEF-NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesMarch 9 (Reuters) - NewcelX AG NCEL.O:NEWCELX ANNOUNCES STRATEGIC COLLABORATI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA7PZPRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618764013","title":"Newcelx Ag - Collaboration to Integrate Ncel-101 With Eledon's Tegoprubart (at-1501)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618764013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618764013?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA7PZPRM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618664092","title":"Newcelx Announces Strategic Collaboration With Eledon Pharmaceuticals to Advance Ncel-101 Program for Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2618664092","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618664092?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA7PZPRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}]}}